What is the recommended acyclovir dose for children with herpetic oral or genital ulcers, including dosing for infants under 3 months and adjustments for impaired renal function?

Acyclovir Pediatric Dosing for Herpetic Ulcers

For children with herpetic oral or genital ulcers, use acyclovir 20 mg/kg per dose (maximum 400 mg/dose) orally three times daily for 5-14 days in children <45 kg, or 400 mg orally twice daily for 5-14 days in adolescents and adults. 1

Dosing by Clinical Presentation

Mild Oral Ulcers (Gingivostomatitis)

• Oral acyclovir: 20 mg/kg/dose (max 400 mg) three times daily for 5-10 days 1
• This applies to children with mild symptomatic disease who can tolerate oral intake
• Treatment should be initiated at the first sign of symptoms for maximum benefit

Moderate to Severe Oral Ulcers

• Start with IV acyclovir: 5-10 mg/kg/dose three times daily 1
• Once lesions begin to regress, transition to oral acyclovir at the same weight-based dosing
• Continue therapy until lesions completely heal
• This approach prevents dehydration and ensures adequate drug levels in children unable to maintain oral intake

Genital Herpes

• Children <45 kg: Acyclovir 20 mg/kg/dose (max 400 mg) orally three times daily for 5-14 days 1
• Adolescents and adults: Acyclovir 400 mg orally twice daily for 5-14 days 1
• The longer duration (up to 14 days) is appropriate for primary episodes
• Episodic treatment of recurrences is usually not necessary in childhood 2

Critical Dosing Considerations

Neonates and Young Infants

The evidence does not provide specific dosing for infants <3 months with mucocutaneous ulcers in the guidelines. However, research indicates:

• Neonates require significantly different dosing due to immature renal function 3, 4
• Elimination half-life in neonates <1 month is 10-15 hours compared to 2.5 hours in older children 3
• For neonates with HSV disease, IV acyclovir is standard, not oral therapy
• If oral suppressive therapy is considered post-treatment, doses of approximately 1340 mg/m²/dose every 12 hours have been used to achieve therapeutic levels 5

Renal Function Adjustments

Dose reduction is mandatory in renal impairment 6:

• Monitor creatinine before and during therapy
• Nephrotoxicity occurs in up to 35% of pediatric patients receiving IV acyclovir 7
• Risk factors for renal dysfunction include:
  • Doses >15 mg/kg 7
  • Age >8 years 7
  • Concomitant nephrotoxic drugs (especially ceftriaxone) 7
• Maintain adequate hydration throughout treatment 6

Weight-Based vs. Fixed Dosing

• The 45 kg threshold distinguishes pediatric from adult dosing 1
• For children <45 kg, always calculate dose by weight (20 mg/kg/dose)
• Cap individual doses at 400 mg to avoid excessive exposure
• For adolescents ≥45 kg, use adult fixed dosing (400 mg twice daily)

Important Clinical Pitfalls

Bioavailability Limitations

• Oral acyclovir has only 10-20% bioavailability, which decreases with increasing doses 6
• This is why higher mg/kg dosing is needed in children compared to adults
• Food does not affect absorption, so acyclovir can be given with or without meals 6

Timing of Initiation

• Treatment must begin within 24-72 hours of symptom onset for maximum efficacy 8, 6
• Delayed treatment significantly reduces benefit
• Counsel families to start therapy at the first sign of prodrome or lesions

Monitoring Requirements

• Baseline and periodic creatinine monitoring, especially with IV therapy 7
• Most renal dysfunction occurs within 48 hours of starting acyclovir 7
• Ensure adequate hydration (oral or IV fluids) to prevent crystalluria 6
• Elderly patients and those with baseline renal impairment require closer monitoring 6

Alternative Agents

• Valacyclovir and famciclovir are approved only for adults and adolescents who can swallow tablets 1
• No pediatric liquid formulations exist for these agents
• These may be considered in older children able to receive adult dosing, though data in children are limited 1
• For acyclovir-resistant HSV (rare), foscarnet 40 mg/kg IV three times daily is the alternative 1

Duration of Therapy

• 5-10 days for mild oral disease 1
• 5-14 days for genital herpes (longer for primary episodes) 1
• Continue until lesions completely heal for moderate-severe disease 1
• Suppressive therapy is generally not indicated in immunocompetent children